Seoul, South Korea

Doo Sik Kim

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2005-2014

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Doo Sik Kim: Innovator in Immune Therapies

Introduction

Doo Sik Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 4 patents, his work focuses on developing compositions that enhance immune responses and treat various medical conditions.

Latest Patents

One of his latest patents is an immune stimulating composition comprising bacterial chromosomal DNA fragments having methylated CpG sequences and non-toxic lipopolysaccharides. This invention relates to a composition that can be industrially applied as effective materials for treating cancers and as an adjuvant. Another notable patent is a composition for treating retinopathy or glaucoma, which comprises thrombin-derived peptides as an effective component. This composition aims to provide a therapeutic solution for individuals suffering from these eye conditions.

Career Highlights

Doo Sik Kim has worked with notable companies such as Eyegene Inc. and Cheiljedang Corporation. His experience in these organizations has allowed him to further his research and development efforts in the field of immunology.

Collaborations

Throughout his career, he has collaborated with esteemed colleagues, including Yang Je Cho and Won Il Yoo. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Doo Sik Kim is a distinguished inventor whose work in immune therapies has the potential to impact the medical field significantly. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…